Cargando…
Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection
Autores principales: | Fishbane, Steven, Hirsch, Jamie S., Nair, Vinay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the National Kidney Foundation, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754454/ https://www.ncbi.nlm.nih.gov/pubmed/35032591 http://dx.doi.org/10.1053/j.ajkd.2022.01.001 |
Ejemplares similares
-
Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022) -
Risks of paxlovid in a heart transplant recipient
por: Stawiarski, Kristin, et al.
Publicado: (2023) -
An explanation for SARS-CoV-2 rebound after Paxlovid treatment
por: Perelson, Alan S., et al.
Publicado: (2023) -
Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection
por: Sun, Fangfang, et al.
Publicado: (2022) -
Mathematical model of SARS-CoV-2 immunity predicts Paxlovid rebound
por: Ranard, Benjamin L., et al.
Publicado: (2023)